Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 11 Feb 2004 |
| Genmab, preliminary announcement of annual report | 5 Feb 2004 |
| Genmab, Announces Year End 2003 Financial Results | 5 Feb 2004 |
| Genmab, Capital increase as a result of employees' warrant exercise. | 5 Feb 2004 |
| Genmab, current statement of shareholdings | 5 Feb 2004 |